16. David Ricks, Eli Lilly

David Ricks
David Ricks became Eli Lilly's CEO at the start of 2017. (LillyPad)

16. David Ricks, Eli Lilly 
2018 pay: $17.23 million 
2017 pay: $15.85 million 
Change: 9% 

As can be said for any biopharma CEO, David Ricks has certainly been busy since taking the helm at the Indianapolis drugmaker. A 22-year company veteran, he became CEO at the start of 2017 and pulled in a $15.85 million pay package that year. 

In his sophomore year at the helm, Ricks earned a 9% raise for a total pay package of $17.23 million. His base salary hit $1.4 million, and his board granted a $3.63 million cash bonus based on financial and pipeline performance. Plus, he netted two performance-based types of equity grants that measure how the company is doing against a peer group that includes AbbVie, Gilead Sciences and Pfizer.  

And while some companies shell out on personal travel for executives, Lilly didn’t record any costs from Ricks’ personal travel last year. He “did not receive any other perquisites,” the filing says.  

Aside from financial performance, Lilly's drug launches and R&D advances are among the factors that determine the drugmaker’s executive pay. 

RELATED: Lilly to cut 3,500 jobs, take a $1.2B hit as it aims for $500M in savings 

Besides overseeing those launches—namely cancer drug Verzenio and immunology therapy Olumiant—Ricks has been busy cutting costs, funneling more cash toward R&D and distributing profits to shareholders.

As Lilly's proxy noted, the CEO “drove a cross-company productivity agenda that funded increased investment in research and development and allowed above-plan capital return to shareholders." That’s likely a reference to the thousands of layoffs and other cuts Lilly put through in recent years to save $500 million annually. Most came in the form of early retirements. 

RELATED: The top 15 pharma companies by 2018 revenue - Eli Lilly

The company release also reported its CEO-to-worker pay ratio for last year. Lilly's median employee compensation came in at $91,246, and Ricks made 189 times that.  

Ricks’ second-year pay bump came during a year of ups and downs for his employer. As its important diabetes business continues to suffer from U.S. pricing pressure, the company is looking to its new launches to pitch in new growth.

RELATED: With revenue growth and cost cuts under his belt, Lilly chief Ricks chalks up $15.8M in pay 

One of them has taken off. Approved in 2016 for psoriasis, immunology drug Taltz is nearing blockbuster territory with 2018 sales of $937 million, despite head-to-head competition against Novartis' powerhouse Cosentyx.

Its new cancer drug Verzenio and another immunology launch, Olumiant, are starting to record meaningful sales, too. Each hit more than $200 million in 2018. And Lilly expects its even newer CGRP drug, Emgality, to serve as a cornerstone of a new migraine and pain franchise. 

All told in 2018, Lilly grew sales 7% to $24.56 billion. Net income for the year came in at $3.23 billion after a $204 million loss in 2017.

16. David Ricks, Eli Lilly

Suggested Articles

It’s been a rocky road for BMS’ immuno-oncology duo in previously untreated lung cancer, but a new addition to the regimen might hold the ticket.

Novartis’ Zolgensma launch has been anything but boring: First a record price, then a data scandal and now a manufacturing-related delay in Europe.

As CEO Paul Hudson focuses Sanofi's R&D program on immuno-oncology and gene therapies, Sanofi is readying a vaccine plant to make viral vectors.